Drug · Small Molecule

Vandetanib

CI-DRUG-00000632Explore in graph →NCIt C2737 CHEMBL24828 CIViC Approved

Regulatory

Approvals (6)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory2 approval records · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as CAPRELSA (DIN 02378582) under ATC L01EX04 VANDETANIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Feb 23, 2012	health-canada-dpd
CA Health Canada	—	Marketed in Canada as CAPRELSA (DIN 02378590) under ATC L01EX04 VANDETANIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Feb 23, 2012	health-canada-dpd

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 18 hours agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	3	1	9	97	6	CA, EU, US	Apr 6, 2011	2002-05
Malignant Thyroid Gland Neoplasm	Approved	Phase 4	2	1	4	12	2	EU, US	Apr 6, 2011	2004-11
Malignant Lung Neoplasm	Phase3	Phase 3	0	0	4	24	0	—	—	2002-10
Malignant Breast Neoplasm	Phase2	Phase 2	1	0	0	7	0

Curated evidence

Clinical evidence (10)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–10 of 10 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
SDHB Mutation1
Metformin + Vandetanib

Clinical trials

Trials with this intervention (99)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 51–99 of 99 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00777179	Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy	completed	Phase 2	117	Genzyme, a Sanofi CompanyINDUSTRY	1	Oct 10, 2016	clinicaltrials
NCT00862836	Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)(ZACFAST)

Molecule

Record

Kind: Small Molecule
Mechanism: Tyrosine-protein kinase SRC inhibitor; Tyrosine-protein kinase BRK inhibitor; Tyrosine-protein kinase TIE-2 inhibitor; Vascular endothelial growth factor receptor inhibitor; Tyrosine-protein kinase receptor RET inhibitor; Ephrin receptor inhibitor; Epidermal growth factor receptor inhibitor
Targets: 25 genes
UNII: YO460OQ37K
Aliases: AZD 6474, AZD6474, Caprelsa, GNF-PF-2188, Lucivand, NSC-744325, NSC-760766, Vandetanib, Zactima, ZD-64, ZD-6474, ZD6474

Data updated 21 hours agoSource updated unknown

Identifiers

Codes (7)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01EX04	VANDETANIB
ATC (WHO)	L01XE	Antineoplastic and immunomodulating agents

AKT2 Amplification1
Everolimus + VandetanibCombination	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	1	accepted	EID1621 Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion… (full text at CIViC) PMID 25982012 · Subbiah et al., 2015 · Open in CIViC	civic

AKT2 Amplification1

Everolimus + VandetanibCombination

Lung Adenocarcinoma

Predictive

Supports Sensitivity Response

accepted

EID1621

Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion… (full text at CIViC)

PMID 25982012 · Subbiah et al., 2015 · Open in CIViC

civic

RET Fusion2
Everolimus + VandetanibCombination	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID1622 Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion… (full text at CIViC) PMID 25982012 · Subbiah et al., 2015 · Open in CIViC	civic
Vandetanib	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID698 A case study of a patient with EGFR, KRAS, BRAF, HER2, ALK, ROS1 and MET negative adenocarcinoma of the lung. FISH analysis revealed a KIF5B-RET fusion. The RET inhibitor Vandetanib led to remission i… (full text at CIViC) PMID 23584301 · Gautschi et al., 2013 · Open in CIViC	civic

RET Fusion2

Everolimus + VandetanibCombination

Lung Adenocarcinoma

Predictive

Supports Sensitivity Response

accepted

EID1622

PMID 25982012 · Subbiah et al., 2015 · Open in CIViC

civic

Vandetanib

Lung Adenocarcinoma

Predictive

Supports Sensitivity Response

accepted

EID698

A case study of a patient with EGFR, KRAS, BRAF, HER2, ALK, ROS1 and MET negative adenocarcinoma of the lung. FISH analysis revealed a KIF5B-RET fusion. The RET inhibitor Vandetanib led to remission i… (full text at CIViC)

PMID 23584301 · Gautschi et al., 2013 · Open in CIViC

civic

RET Fusion + RET G810A1
Vandetanib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Does Not Support Resistance	3	submitted	EID4852 We established inducible KIF5B-RET transgenic mice and KIF5B-RET-dependent cell lines for preclinical modeling of KIF5B-RET-associated lung adenocarcinoma. By culturing cells with increasing concentra… (full text at CIViC) PMID 27496134 · Huang et al., 2016 · Open in CIViC	civic

RET Fusion + RET G810A1

Vandetanib

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Does Not Support Resistance

submitted

EID4852

We established inducible KIF5B-RET transgenic mice and KIF5B-RET-dependent cell lines for preclinical modeling of KIF5B-RET-associated lung adenocarcinoma. By culturing cells with increasing concentra… (full text at CIViC)

PMID 27496134 · Huang et al., 2016 · Open in CIViC

civic

RET Fusion2
Vandetanib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID4848 RET rearrangements involving RET are found in about 1% of NSCLC and define a unique molecular subset. This study was a multi-center, open-label, phase II clinical trial to examine the safety and effi… (full text at CIViC) PMID 27803005 · Lee et al., 2017 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID4849 We aimed to assess the efficacy and safety of vandetanib in patients with advanced RET-rearranged NSCLC. In this open-label, multicentre, phase 2 trial (LURET), patients with advanced RET-rearranged N… (full text at CIViC) PMID 27825616 · Yoh et al., 2017 · Open in CIViC	civic

RET Fusion2

Vandetanib

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID4848

RET rearrangements involving RET are found in about 1% of NSCLC and define a unique molecular subset. This study was a multi-center, open-label, phase II clinical trial to examine the safety and effi… (full text at CIViC)

PMID 27803005 · Lee et al., 2017 · Open in CIViC

civic

〃

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID4849

We aimed to assess the efficacy and safety of vandetanib in patients with advanced RET-rearranged NSCLC. In this open-label, multicentre, phase 2 trial (LURET), patients with advanced RET-rearranged N… (full text at CIViC)

PMID 27825616 · Yoh et al., 2017 · Open in CIViC

civic

RET Overexpression2
Vandetanib	Malignant Breast Neoplasm	Predictive	D	Supports Sensitivity Response	2	accepted	EID740 Vandetanib was tested in 4 murine models of patient-derived xenografts. In xenografts with high expression of EGFR or RET, vandetanib led to tumor regression, in those without high expression, vandeta… (full text at CIViC) PMID 26686064 · Hatem et al., 2016 · Open in CIViC	civic
〃	Estrogen Receptor-negative Breast CancerUNRESOLVED	Predictive	D	Supports Sensitivity Response	3	submitted	EID2992 The activity of Vandetanib was tested in vivo in three PDX models of TNBC and one model of HER2+ BC with different expression levels of RET and EGFR. Vandetanib induced tumor regression in PDX models … (full text at CIViC) PMID 26686064 · Hatem et al., 2016 · Open in CIViC	civic

RET Overexpression2

Vandetanib

Malignant Breast Neoplasm

Predictive

Supports Sensitivity Response

accepted

EID740

Vandetanib was tested in 4 murine models of patient-derived xenografts. In xenografts with high expression of EGFR or RET, vandetanib led to tumor regression, in those without high expression, vandeta… (full text at CIViC)

PMID 26686064 · Hatem et al., 2016 · Open in CIViC

civic

〃

Estrogen Receptor-negative Breast CancerUNRESOLVED

Predictive

Supports Sensitivity Response

submitted

EID2992

The activity of Vandetanib was tested in vivo in three PDX models of TNBC and one model of HER2+ BC with different expression levels of RET and EGFR. Vandetanib induced tumor regression in PDX models … (full text at CIViC)

PMID 26686064 · Hatem et al., 2016 · Open in CIViC

civic

PDGFRB Fusion1
Erlotinib + Gefitinib + Ibrutinib + VandetanibSubstitutes	T Acute Lymphoblastic LeukemiaCURATED_BROADER	Predictive	D	Does Not Support Sensitivity Response	3	submitted	EID13006 Ba/F3 cells with AGGF1:PDGFRb showed IL3 independent growth. Patient derived cells and Ba/F3, both with AGGF1:PDGFRb, were treated with erlotinib, gefitinib, ibrutinib, and vandetanib. IC50 for inhibi… (full text at CIViC) PMID 29284681 · Zabriskie et al., 2018 · Open in CIViC	civic

PDGFRB Fusion1

Erlotinib + Gefitinib + Ibrutinib + VandetanibSubstitutes

T Acute Lymphoblastic LeukemiaCURATED_BROADER

Predictive

Does Not Support Sensitivity Response

submitted

EID13006

Ba/F3 cells with AGGF1:PDGFRb showed IL3 independent growth. Patient derived cells and Ba/F3, both with AGGF1:PDGFRb, were treated with erlotinib, gefitinib, ibrutinib, and vandetanib. IC50 for inhibi… (full text at CIViC)

PMID 29284681 · Zabriskie et al., 2018 · Open in CIViC

civic